Biopharma’s winners and losers of 2025news2025-12-18T16:20:28+00:00December 18th, 2025|Endpoints News|
Takeda’s $4B immunology drug achieves first Phase 3 successesnews2025-12-18T15:58:06+00:00December 18th, 2025|Endpoints News|
Subcutaneous Rybrevant; Kalaris shares nAMD data; Pyxis disappointsnews2025-12-18T15:47:22+00:00December 18th, 2025|Endpoints News|
Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series Anews2025-12-18T14:57:00+00:00December 18th, 2025|Endpoints News|
Erasmus+ programme to reopen to UK student in 2027news2025-12-18T14:30:00+00:00December 18th, 2025|Chemistry World|
Atavistik raises $120M for bleeding disorder, blood cancer drugsnews2025-12-18T13:59:04+00:00December 18th, 2025|Endpoints News|
LNG Market Report: Asia premium to Europe falls on limited demandnews2025-12-18T13:57:00+00:00December 18th, 2025|Independent Commodity Intelligence Services (ICIS)|
